Codiak Biosciences Inc

NASDAQ:CDAK   3:59:42 PM EDT
8.90
+0.33 (+3.85%)
Earnings Announcements

Codiak Biosciences Reports Third Quarter 2020 Financial Results And Operational Progress

Published: 11/19/2020 21:27 GMT
(CDAK) - Codiak Biosciences Reports Third Quarter 2020 Financial Results and Operational Progress.
Q3 Revenue $1.0 Million Versus $200,000.
Codiak Biosciences - Initial Safety Results and Preliminary Systemic Exposure/pharmacokinetics of Exoil-12 in Healthy Volunteers Anticipated Ye 2020.
Biomarker, Safety and Clinical Outcome Results in Cancer Patients Anticipated Mid-2021 for Both Exosting and Exoil-12.
Qtrly Loss per Share $12.83.
Revenue is expected to be $0.52 Million
Adjusted EPS is expected to be -$1.46

Next Quarter Revenue Guidance is expected to be $0.52 Million
Next Quarter EPS Guidance is expected to be -$1.22

More details on our Analysts Page.